Skip to content

Transcutaneous electrical acupoint stimulation for postoperative urinary retention after anorectal surgery: a randomized controlled trial

Transcutaneous electrical acupoint stimulation for postoperative urinary retention after anorectal surgery: a randomized controlled trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2025001795
Enrollment
Unknown
Registered
2025-09-21
Start date
2025-09-29
Completion date
Unknown
Last updated
2025-10-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Postoperative urinary retention

Interventions

Sham transcutaneous electrical acupoint stimulation group:Bilateral Sanyinjiao and Shuiquan 2cm apart, no current output, 30 minutes
Neostigmine group:Neostigmine injection into gluteus maximus muscle, approximately 1mg
Transcutaneous electrical acupoint stimulation group:Bilateral Sanyinjiao and Shuiquan continuous wave 10Hz 30 minutes

Sponsors

Hospital of Chengdu University of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: (1)18-65 years old; (2) met the diagnostic criteria for postoperative urinary retention; (3) underwent anorectal surgery; (4) did not use any other medication to promote urination after surgery; (5) patients with good compliance during hospitalization able to take care of their own lives and willing to undergo the present study; and (6) patients who signed the informed consent form by themselves or on behalf of their immediate family members.

Exclusion criteria

Exclusion criteria: (1) With other causes of urinary retention such as prostatic hyperplasia urinary stones chronic renal failure renal tumors and so on; (2) Patients with severe urinary tract infection; (3) Patients with combined severe cardiovascular disease hepatic and renal insufficiency and poor coagulation function; (4) Patients with pacemakers coagulation disorders history of epilepsy or patients with partial sensory loss;(5) Patients who have experienced allergy to Neostigmine Methylsulfate Injection or who have experienced adverse reactions caused by the use of the drug; (6) Those who suffer from mental disorders; (7) Menstruating pregnant or lactating women; (8) Those who have participated in or are participating in other clinical trials within the past month that may interfere with this trial.

Design outcomes

Primary

MeasureTime frame
First urine volume;Time of first urination;

Secondary

MeasureTime frame
Patency of urination;Bladder residual urine volume;Patient symptoms and signs score;Visual analogue scale;

Countries

China

Contacts

Public ContactZheng Hui

Chengdu University of Traditional Chinese Medicine

zhenghui@cdutcm.edu.cn18011503380

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026